Screening for prostate cancer using prostate-specific antigen testing in Japanese men on hemodialysis

Kurahashi, Toshifumi; Shinozaki, Masashi; Oka, Noriko; Takenaka, Atsushi; Hara, Isao; Matsumura, Yosuke; Fujisawa, Masato

doi:10.1007/s11255-007-9246-2

Cited by 5 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Furthermore, the age of patients with renal failure has increased with progression in the field of therapy, suggesting a proportional increase in the prevalence of prostate cancer among these patients. 17 Recently, it is also reported that in patients with renal failure age-stratified PSA was higher than in the general population. And the cancer detection rate was increased in patients with renal failure compared to that in patients with normal renal function at specific PSA intervals.…”

Section: Discussionmentioning

confidence: 97%

Cancer detection rates of different prostate biopsy regimens in patients with renal failure

Hoşcan¹,

Özorak²,

Oksay³

et al. 2014

Renal Failure

View full text Add to dashboard Cite

We aimed to evaluate the cancer detection rates of 6-, 10-, 12-core biopsy regimens and the optimal biopsy protocol for prostate cancer diagnosis in patients with renal failure. A total of 122 consecutive patients with renal failure underwent biopsy with age-specific prostate-specific antigen (PSA) levels up to 20 ng/mL. The 12-core biopsy technique (sextant biopsy + lateral base, lateral mid-zone, lateral apex, bilaterally) performed to all patients. Pathology results were examined separately for each sextant, 10-core that exclude parasagittal mid-zones from 12-cores (10a), 10-core that exclude apex zones from 12-cores (10b) and 12-core biopsy regimens. Of 122 patients, 37 (30.3%) were positive for prostate cancer. The cancer detection rates for sextant, 10a, 10b and 12 cores were 17.2%, 29%, 23.7% and 30.7%, respectively. Biopsy techniques of 10a, 10b and 12 cores increased the cancer detection rates by 40%, 27.5% and 43.2% among the sextant technique, respectively. Biopsy techniques of 10a and 12 cores increased the cancer detection rates by 17.1% and 21.6% among 10b biopsy technique, respectively. There were no statistical differences between 12 core and 10a core about cancer detection rate. Adding lateral cores to sextant biopsy improves the cancer detection rates. In our study, 12-core biopsy technique increases the cancer detection rate by 5.4% among 10a core but that was not statistically different. On the other hand, 12-core biopsy technique includes all biopsy regimens. We therefore suggest 12-core biopsy or minimum 10-core strategy incorporating six peripheral biopsies with elevated age-specific PSA levels up to 20 ng/mL in patients with renal failure.

show abstract

Section: Discussionmentioning

confidence: 97%

Cancer detection rates of different prostate biopsy regimens in patients with renal failure

Hoşcan¹,

Özorak²,

Oksay³

et al. 2014

Renal Failure

View full text Add to dashboard Cite

show abstract

“…An active PC screening, especially in dialysis and transplant patients with ESRD is based on the fact that patients with PC-ESRD usually presented at a more advanced clinical stage and a grade ≥2 (47–55.3% and 45%, respectively, in our study). Moreover, they had an increased tumor volume, shown by the percentage of positive biopsy scores, rapid malignant cell proliferation, aggressive biochemical behavior, and a higher susceptibility to infections [ 8 , 19 , 20 ]. Our study also showed that 62.6% of transplanted PC-ESRD patients were diagnosed with locally advanced or advanced PC.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and survival prognosis of prostate cancer in patients with end-stage renal disease: a retrospective study based on the Korea national database (2003-2010)

et al. 2017

View full text Add to dashboard Cite

ObjectiveThe study was aimed to evaluate the prevalence and prognosis of prostate cancer (PC) and end-stage renal disease (ESRD), determine the risk factors for overall survival (OS) and PC-specific survival (CSS), and evaluate differences in PC-related clinical therapeutic patterns between patients with and without PC-ESRD.MethodsThis observational population study, performed at the National Cancer Center and Cancer Research Institute in Korea, included patients with PC and ESRD from the nationwide Korean Health Insurance System and Korean Central Cancer Registry data. Five-year overall and cancer-specific survival. A joinpoint regression analysis was performed to predict incidence and mortality of PC. Survival was analyzed using Kaplan-Meir curves with log rank tests of patients with dialysis or transplantation.ResultsOf 3945 patients with PC-ESRD, 3.9% were on dialysis (N=152), 0.2% had kidney transplantation (N=10, D-TPL group); 3783 (95.9%) had neither dialysis nor transplantation (non-D-TPL ESRD group). There were 697 PC-specific deaths. The median respective OS, PC-specific survival, and 5-year survival rates in the non-ESRD, non-D-TPL ESRD, dialysis ESRD, and transplantation ESRD groups were significantly different (p<0.001). Presence of ESRD, age, body mass index, SEER stage, no treatment within 6 months after diagnosis, no surgery, chemotherapy, radiotherapy or hormonal therapy, non-adenocarcinoma pathology, and Charlson comorbidity index were independent risk factors for OS and CSS.ConclusionsWith a 10.1% nationwide prevalence of PC-ESRD, the presence of ESRD was a significant survival factor along with other significant clinicopathological factors.

show abstract

Section: Commentmentioning

confidence: 99%

“…greater increases in tPSA levels (8), no changes in tPSA (9,10) or even lower levels of tPSA (11) as well as increases in fPSA (9,10,(12)(13)(14)(15)(16)(17), especially in older patients. Some investigations reported increased (7,18,19) or similar (20) risk of prostate cancer detection rates. Such differences seem to be induced by age (7,11,18), tPSA levels (8) and degree of decreased renal function (14,20), so all of these factors should be taken into consideration when determining whether performing prostate biopsy is necessary for a patient with CKD.…”

Section: What's Newmentioning

confidence: 99%

“…No differences in tumour aggressiveness were noted in our comparative analysis according to GFR levels. A previous study (19) investigated 115 male haemodialysis patients and reported that prostate cancer detected in haemodialysis patients tends to be relatively advanced. Joseph et al reported that men with prostate cancer who had %fPSA > 25% had less aggressive disease, whereas men with %fPSA < 10% had more aggressive disease (14).…”

Section: Diminished Renal Function and Psa Isoformsmentioning

confidence: 99%

See 1 more Smart Citation

Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml

Cho¹,

Park²,

Lee³

et al. 2013

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

Screening for prostate cancer using prostate-specific antigen testing in Japanese men on hemodialysis

Cited by 5 publications

References 17 publications

Cancer detection rates of different prostate biopsy regimens in patients with renal failure

Cancer detection rates of different prostate biopsy regimens in patients with renal failure

Prevalence and survival prognosis of prostate cancer in patients with end-stage renal disease: a retrospective study based on the Korea national database (2003-2010)

Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml

Contact Info

Product

Resources

About